贵州医科大学学报

2017, v.42;No.207(12) 1465-1468+1477

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

曲美他嗪辅助治疗糖尿病心肌病156例临床分析
Trimetazidine Treatment of 156 Patients with Diabetic Cardiomyopathy

郑焱玲;陈刘;刘颖;唐能华;欧敏;雷小添;程立庆;龙崇荣;
ZHENG Yanling;CHEN Liu;LIU Ying;TANG Nenghua;OU Min;LEI Xiaotian;CHENG Liqing;LONG Chongrong;Endocrine Department,the Southwest Hospital of the 3rd Military Medical University;Endocrine Department,People's Hospital of Shapingba District;

摘要(Abstract):

目的:观察曲美他嗪辅助治疗糖尿病心肌病(DC)的临床疗效。方法:将156例DC患者按随机数字法分为治疗组(81例)与对照组(75例),采用常规内科治疗;治疗组在常规内科治疗基础上口服曲美他嗪,测定治疗前后各组的空腹血糖、糖化血红蛋白、总胆固醇、甘油三酯、低密度脂蛋白、高密度脂蛋白、E/A比值、心电图Q-T离散度(Q-Td),超敏C反应蛋白(HsCRP)和肿瘤坏死因子(TNF-α)。结果:与治疗前比较,两组患者治疗后血糖、总胆固醇、甘油三酯、LDL、HDL均较治疗前有所改善(P<0.05),其中治疗组总胆固醇、甘油三酯、LDL、HDL改善幅度较对照组大(P<0.05);Q-Td均较治疗前有所降低(P<0.05),其中治疗组降低幅度较对照组幅度大(P<0.05);E/A比值均较治疗前有显著增高(P<0.05),其中治疗组改善幅度较对照组显著(P<0.05);HsCRP和TNF-α均较治疗前下降明显(P<0.05),其中治疗组HsCRP和TNF-α改善幅度与对照组相比更为明显(P<0.05)。结论:曲美他嗪对临床糖尿病心肌病有一定辅助治疗效果。
Objective: To investigate the efficacy of Trimetazidine in 156 patients with diabetic cardiomyopathy. Methods: 156 patients were randomly divided into Trimetazidine treatment group( n =81) and the control group( n = 75),both received conventional medical treatment. Treatment group received further Trimetazidine treatment. Blood glucose,HbA1C,blood lipids( total cholesterol,triglycerides,LDL,HDL),E/A ratio,ECG QT dispersion,High-sensitive C-reactive protein( HsCRP)and TNF-αwere tested before and after treatment. Results: Compared with before treatment,blood glucose,total cholesterol,triglycerides,LDL,HDL were improved significantly in both group after treatment( P < 0. 05); in treatment group,total cholesterol,triglycerides,LDL,HDL improved much more than control group( P < 0. 05); QT dispersion decreased compared with before treatment( P < 0.05),of which treatment decreased much more tan control group( P < 0. 05); E/A ratio improved compared with before treatment( P < 0. 05),of which treatment group improved much more than control group( P < 0. 05); HsCRP and TNF-αdecreased compared with before treatment( P < 0. 05),of which HsCRP and TNF-α improvement were more obvious compared with control group( P < 0. 05). Conclusion: Trimetazidine can assist the treatment of diabetic cardiomyopathy.

关键词(KeyWords): 曲美他嗪;糖尿病;心肌病;治疗效果;心功能;超敏C反应蛋白;肿瘤坏死因子
trimetazidine;diabetes;cardiomyopathy;curative effects;heart function;hypersensitive C reactive protein;tumor necrosis factor

Abstract:

Keywords:

基金项目(Foundation): 中华医学会临床医学科研专项资金(13040630448);; 中华国际医学交流基金会青年医生糖尿病研究项目(2015-N-08)

作者(Author): 郑焱玲;陈刘;刘颖;唐能华;欧敏;雷小添;程立庆;龙崇荣;
ZHENG Yanling;CHEN Liu;LIU Ying;TANG Nenghua;OU Min;LEI Xiaotian;CHENG Liqing;LONG Chongrong;Endocrine Department,the Southwest Hospital of the 3rd Military Medical University;Endocrine Department,People's Hospital of Shapingba District;

Email:

DOI: 10.19367/j.cnki.1000-2707.2017.12.023

参考文献(References):

文章评论(Comment):

序号(No.) 时间(Time) 反馈人(User) 邮箱(Email) 标题(Title) 内容(Content)
反馈人(User) 邮箱地址(Email)
反馈标题(Title)
反馈内容(Content)
扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享